![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*750xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Teva attracts attention from pharma, private equity for $500M sale of Medis: Bloomberg | Fierce Pharma Teva attracts attention from pharma, private equity for $500M sale of Medis: Bloomberg | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1536847668/headache-1540220_1920.jpg/headache-1540220_1920.jpg?VersionId=30I3spvJFHYaM83l.cBTFaeySwk0X.Rh)
Teva attracts attention from pharma, private equity for $500M sale of Medis: Bloomberg | Fierce Pharma
![Teva Pharmaceutics USA acquires three buildings for an R&D campus in West Chester - Philadelphia Business Journal Teva Pharmaceutics USA acquires three buildings for an R&D campus in West Chester - Philadelphia Business Journal](https://media.bizj.us/view/img/6047051/img0195*1200xx2490-1403-0-608.jpg)
Teva Pharmaceutics USA acquires three buildings for an R&D campus in West Chester - Philadelphia Business Journal
![An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma – topic of research paper in Clinical medicine. Download scholarly article PDF An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma – topic of research paper in Clinical medicine. Download scholarly article PDF](https://cyberleninka.org/viewer_images/283484/f/1.png)